一类多肽偶联药物及其制备方法和应用
By designing peptide-conjugated drugs, AIP-IIID4A amide cyclic peptides are linked to antibiotics to achieve bacterial targeting and release of high concentrations of antibiotics intracellularly. This solves the problem that existing antibiotics cannot clear intracellular bacteria and has the advantages of simplified synthesis and reduced immunogenicity.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- FOURTH MILITARY MEDICAL UNIVERSITY
- Filing Date
- 2024-12-25
- Publication Date
- 2026-07-17
AI Technical Summary
Existing antibiotics are ineffective at eliminating intracellular infections of Staphylococcus aureus, leading to drug resistance and increased patient burden with long-term use. Existing drug delivery strategies suffer from poor targeting specificity and immunogenicity issues.
A peptide-conjugated drug was designed, using AIP-IIID4A amide cyclic peptide as a target, which was linked to an antibiotic via click chemistry. The linker arm was specifically hydrolyzed in the lysosome, achieving bacterial targeting and releasing high concentrations of antibiotics intracellularly.
It achieves co-localization of antibiotics and bacteria within cells, efficiently eliminates intracellular bacteria, simplifies drug synthesis, reduces the risk of immunogenicity, and has good antibacterial effects.
Smart Images
Figure CN119701000B_ABST